Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • 372 Single-agent anti-tumor ac...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager

372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager

Bibliographic Details
Main Authors: Victoria Smith, Patrick Chun, Alexander Starodub, Sarina Piha-Paul, Raghad Karim, Michael Shafique, Gabriel Tinoco Suarez, Curtis Ruegg
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • 692 AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response
    by: Victoria Smith, et al.
    Published: (2020-11-01)
  • The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
    by: Sun F, et al.
    Published: (2020-07-01)
  • 782-F Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102: an interim report of the single-agent cohort in Phase I clinical trial
    by: Tatsuro Tajiri, et al.
    Published: (2023-11-01)
  • 724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)
    by: Aranzazu Manzano, et al.
    Published: (2023-11-01)
  • Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience
    by: Uğur Demirsoy, et al.
    Published: (2019-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs